- Report
- April 2025
- 235 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- April 2025
- 250 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- March 2025
- 175 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- August 2024
- 149 Pages
Global
From €2729EUR$2,999USD£2,340GBP
- Report
- July 2024
- 200 Pages
Global
From €4504EUR$4,949USD£3,861GBP
- Report
- January 2024
- 200 Pages
Global
From €3777EUR$4,150USD£3,238GBP
- Report
- February 2024
- 112 Pages
Global
From €4323EUR$4,750USD£3,706GBP
- Report
- February 2024
- 83 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- November 2021
- 844 Pages
Global
From €4551EUR$5,000USD£3,901GBP
Glatiramer acetate is a synthetic drug used to treat multiple sclerosis (MS). It is a mixture of four amino acids that are similar to those found in myelin, the protective sheath that covers nerve fibers. The drug works by reducing the inflammation and damage to the myelin sheath caused by MS. It is administered as an injection and is usually taken once a day.
Glatiramer acetate is a relatively new drug, but it has become increasingly popular in the Central Nervous System (CNS) drugs market. It is used to treat relapsing-remitting MS, a form of the disease that is characterized by periods of remission and relapse. It is also used to treat primary progressive MS, a form of the disease that is characterized by a gradual worsening of symptoms.
Glatiramer acetate is available in both generic and branded forms. Some of the companies that produce glatiramer acetate include Teva Pharmaceuticals, Mylan, and Sandoz. Show Less Read more